The Cytometry and Antibody Technology (CAT) Facility?s mission is to support the community of researchers at the University of Chicago with: 1) cutting-edge technology operated by expertly trained personnel; 2) high- quality analytical monoclonal antibodies; and 3) expert technical consultation and training of researchers. The Facility is utilized by University of Chicago Medicine Comprehensive Cancer Center (UCCCC) investigators conducting basic and translational research of cellular phenotype and function. The CAT Facility serves the UCCCC membership by providing tools necessary to measure the properties of cells and their products. This includes the technology and staff expertise to use these reagents for experimental measurements (flow cytometers, mass cytometer, image cytometers, cell sorters and multiplex analyzers), as well as reagents used to label the cells (antibody/hybridoma bank that provides commonly used, highest quality purified antibodies, purification of existing monoclonals, and fluorescently coupled antibodies). Multiparameter analysis of single cells has become a standard tool in cancer research. Flow cytometry technology now allows for the measurements of more than 15 different markers simultaneously. With imaging flow cytometry (e.g., Amnis ImageStream), the CAT Facility can also capture images of the analyzed cells and develop clinical or research assays based on the expression of these markers as well as on their distribution. With mass cytometry, more than 40 parameters on a single cell can be measured to obtain an unequalled amount of information for each and every cell analyzed. Specific Core accomplishments during the current funding period include obtaining a new BD FACsFortessa for 15 color flow cytometry, an Aria Fusion for sorting human samples for translational studies, and a new CyTOF Helios mass cytometer that was funded by a successful NIH S10 award. The Facility?s Scientific and Technical Directors provide direct oversight of the operation of the CAT Facility. A Faculty Oversight Committee (FOC) also provides an advisory role to the Facility personnel with regards to services, scientific direction and fiscal issues. The Office of Shared Research Facilities (OSRF) serves as the home department for the Facility, providing IT and HR support, accountancy services, and strategic planning. The Research Resources Oversight Committee (RROC) is a faculty committee that provides scientific and financial oversight of all BSD Cores, and provides long-term strategic planning of Core services and resources. Future plans for the CAT facility include improving direct contact with the research community to present information about the Facility and better understand the needs of our user base, development of CyTOF panels and reagents, and advancing as a cutting edge facility by incorporating new technology, while providing our successful base core services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-45
Application #
9904505
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :

Showing the most recent 10 out of 668 publications